openPR Logo
Press release

Deadline on April 11th coming up in Lawsuit for Investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC)

03-28-2022 06:26 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on April 11, 2022 in the lawsuit for certain investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC).

A Deadline is coming up on April 11, 2022 in the lawsuit for certain investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC).

A deadline is coming up on April 11, 2022 in the lawsuit filed for certain investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC).

Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and there are strict and short deadlines running. Deadline: April 11, 2022. NASDAQ: FENC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Middle District of North Carolina the plaintiff alleges on behalf of purchasers of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) common shares between May 28, 2021 and November 26, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 28, 2021 and November 26, 2021, the Defendants made false and/or misleading statements and/or failed to disclose that Fennec Pharmaceuticals Inc. had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, that as a result, the FDA was unlikely to approve the Resubmitted Pedmark NDA, that accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on April 11th coming up in Lawsuit for Investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) here

News-ID: 2589157 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Fennec

Hepatoblastoma Market Growing Rapidly by - Eureka Therapeutics, Fennec Pharmaceu …
DataM Intelligence has published a new research report on "Hepatoblastoma Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/hepatoblastoma-market The
Investigation announced for Long-Term Investor in shares of Fennec Pharmaceutica …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Fennec Pharmaceuticals Inc.. Investors who are current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: FENC stocks follows a lawsuit filed against Fennec
Lawsuit filed for Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FE …
An investor, who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), filed a lawsuit over alleged Securities Laws violations by Fennec Pharmaceuticals Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and for certain investors are short and strict deadlines running. Deadline: April 11, 2022. NASDAQ: FENC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call
Investigation announced for Investors in shares of Fennec Pharmaceuticals Inc. ( …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Fennec Pharmaceuticals Inc. Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Fennec Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders. North Carolina
Investigation announced for Long-Term Investors in shares of Fennec Pharmaceutic …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Fennec Pharmaceuticals Inc.. Investors who are current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: FENC stocks follows a lawsuit filed against Fennec Pharmaceuticals Inc
Lawsuit filed for Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FE …
An investor, who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), filed a lawsuit over alleged violations of Federal Securities Laws by Fennec Pharmaceuticals Inc. Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and for certain investors are short and strict deadlines running. Deadline: November 02, 2020. NASDAQ: FENC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On August 11,